Provention Bio (Provention Bio) EBIT per Share : $-1.71 (TTM As of Dec. 2022)

View and export this data going back to 2018. Start your Free Trial

What is Provention Bio EBIT per Share?

Provention Bio's EBIT per Share for the three months ended in Dec. 2022 was $-0.44. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2022 was $-1.71.

During the past 3 years, the average EBIT per Share Growth Rate was -16.30% per year. During the past 5 years, the average EBIT per Share Growth Rate was -37.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Provention Bio's EBIT per Share or its related term are showing as below:

PRVB' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -91.6 Med: -16.3 Max: -15.3
Current: -16.3

During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Provention Bio was -15.30% per year. The lowest was -91.60% per year. And the median was -16.30% per year.

PRVB's 3-Year EBIT Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 3.5 vs PRVB: -16.30

Provention Bio's EBIT for the three months ended in Dec. 2022 was $-38.83 Mil.

Provention Bio EBIT per Share Historical Data

The historical data trend for Provention Bio's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provention Bio EBIT per Share Chart

Provention Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT per Share

Get a 7-Day Free Trial

-1.20

-1.09

-1.89

-1.83

-1.69

Provention Bio Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
EBIT per Share	Get a 7-Day Free Trial															-0.41	-0.46	-0.46	-0.34	-0.44

Provention Bio EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Provention Bio's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-125.92	/	74.723
=	-1.69

Provention Bio's EBIT per Share for the quarter that ended in Dec. 2022 is calculated as

	EBIT per Share		(Q: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-38.831	/	87.440
=	-0.44

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.71

Provention Bio (NAS:PRVB) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Provention Bio EBIT per Share Related Terms

Thank you for viewing the detailed overview of Provention Bio's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Provention Bio (Provention Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Provention Bio Inc (NAS:PRVB) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

55 Broad Street, 2nd Floor, Red Bank, NJ, USA, 07701

Website

https://www.proventionbio.com

Provention Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease, including oncological, autoimmune, and inflammatory diseases. The company's product candidates include PRV-031, for the interception, delay, or prevention of type 1 diabetes; PRV-3279, for the potential treatment of systemic lupus erythematosus; and PRV-101.

Executives

Sessa Capital (master), L.p.	10 percent owner	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Ashleigh Palmer	director, 10 percent owner, officer: President and CEO	PROVENTION BIO, INC., 110 OLD DRIFTWAY LANE, LEBANON NJ 08833
Francisco Leon	director, 10 percent owner, officer: Chief Scientific Officer	C/O PROVENTION BIO, INC., 110 OLD DRIFTWAY LANE, LEBANON NJ 08833
Jason Hoitt	officer: Chief Commercial Officer	C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707
Justin Vogel	officer: Chief Accounting Officer	C/O PROVENTION BIO, INC., 55 BROAD STREET, RED BANK NJ 07701
Rita Jain	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Sarah O'brien	officer: Chief People Officer	C/O PROVENTION BIO, INC., 55 BROAD STREET, RED BANK NJ 07701
Sessa Capital Im, L.p.	10 percent owner	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
John Petry	10 percent owner	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Gp, Llc	10 percent owner	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Im Gp, Llc	10 percent owner	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Miyoko Christina Yi	officer: Chief Operations Officer	C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK NJ 07701
Benedict Osorio	officer: Chief Quality Officer	ONE WORLD TRADE CENTER, 47TH FLOOR, SUITE J, NEW YORK NY 10007
Eleanor Ramos	officer: Chief Medical Officer & COO	ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE E, SEATTLE WA 98102
Thierry Chauche	officer: Chief Financial Officer	C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK NJ 07701